Valo C1
Alternative Names: Neoantigen coated adenovirus vaccine - Valo Therapeutics; ValoC1Latest Information Update: 28 Jul 2023
At a glance
- Originator Valo Therapeutics
- Class Cancer vaccines; Immunotherapies; Oncolytic viruses; Peptide vaccines
- Mechanism of Action CD8 positive T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for preclinical development in Cancer in Finland (Parenteral)
- 28 Jul 2023 No recent reports of development identified for preclinical development in Cancer in United Kingdom (Parenteral)
- 06 Jan 2022 Valo Therapeutics acquires PeptiCRAdTM technology from University of Helsinki